Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Breast cancer, metastatic

2627 - Impact of palbociclib plus letrozole on health related quality of life (HRQOL) compared with letrozole alone in treatment naïve postmenopausal patients with ER+ HER2- metastatic breast cancer (MBC): results from PALOMA-2


09 Oct 2016


Breast cancer, metastatic


Hope Rugo


Annals of Oncology (2016) 27 (6): 68-99. 10.1093/annonc/mdw365


H. Rugo1, V. Dieras2, K.A. Gelmon3, R. Finn4, D. Slamon5, M. Miguel6, P. Neven7, J. Ettl8, Y. Shparyk9, A. Mori10, D.R. Lu11, H. Bhattacharyya12, C.H. Bartlett13, S. Iyer14, S. Johnston15, N. Harbeck16

Author affiliations

  • 1 Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, 94115 - San Francisco/US
  • 2 Department Of Medical Oncology, Institut Curie, 75248 - Paris/FR
  • 3 Medical Oncology, British Columbia Cancer Agency, V5Z 4E6 - Vancouver/CA
  • 4 Medical Oncology, UCLA - School of Medicine, 90095 - Los Angeles/US
  • 5 Hematology/oncology, UCLA Medical Center, Santa Monica, Santa Monica/US
  • 6 Medical Oncology Service, Hospital General Universitario Gregorio Marañon, Madrid/ES
  • 7 Oncology, University Hospitals Leuven - Campus Gasthuisberg, Leuven/BE
  • 8 Oncology, Technische Universität München, München/DE
  • 9 Department Of Chemotherapy, Lviv State Regional Treatment and Diagnostics Oncology Center, 79031 - Lviv/UA
  • 10 Clinical Development, Pfizer, Milano/IT
  • 11 Biostatistics, Pfizer, La Jolla/US
  • 12 Statistics, Pfizer,Inc, New York/US
  • 13 Global Medical, Pfizer,Inc, New York/US
  • 14 Global Outcomes & Evidence, Pfizer, Inc, New York/US
  • 15 Medical Oncology, Royal Marsden Hospital NHS Foundation Trust, London/GB
  • 16 Breast Center, University of Munich, 81377 - Munich/DE


Abstract 2627


Palbociclib plus letrozole significantly improved progression free survival (PFS) compared to letrozole alone in the phase III PALOMA-2 trial. QOL is a critical consideration when adding targeted agents to hormone therapy in metastatic breast cancer (MBC). We compared patient reported HRQOL in treatment naïve postmenopausal patients with ER + , HER2- MBC in PALOMA-2 (Pfizer: NCT01740427).


PALOMA-2 randomized patients 2:1 to palbociclib + letrozole (N= 444) or placebo + letrozole (N= 222). Patient reported outcomes were assessed at baseline, day 1 of cycle 2, 3 and day 1 of every other cycle from cycle 5 until end of treatment using the Functional Assessment of Cancer Therapy – Breast (FACT-B) questionnaire. FACT-B includes FACT-General (FACT-G) and BC-specific subscale (BCS). FACT-B produces five subscale scores: physical well-being (PWB), social/family well-being (SWB), emotional well-being (EWB), functional wellbeing (FWB), and a BC subscale (BCS), used to derive overall FACT-B, FACT-G, and Trial Outcome Index (TOI) scores. A higher score indicates a better QOL. Repeated measures mixed-effects analyses were performed to compare between treatments change from baseline in each subscale and FACT-B scores, controlling for baseline.


Baseline scores were comparable between the two treatment arms for FACT-B (102 vs 103), FACT- G, TOI and each of the subscale scores. There were no significant differences between the treatment groups in change from baseline scores for PWB (-0.5 vs. -0.3; p= 0.414), SWB (-0.6 vs -0.7; p = 0.762), EWB (0.7 vs 0.5;p = 0.538) and FWB (0.2 vs 0.3;p = 0.707). Overall change from baseline scores was comparable for the BCS (0.19 vs 0.83; p =0.055), Trial Outcome Index (-0.1 vs 0.71; p= 0.325), FACT- G (-0.39 vs -0.53; p = 0.882) and FACT-B (-0.11 vs 0.22; p = 0.782) scores.


The addition of palbociclib to letrozole maintains HRQOL in treatment naïve postmenopausal patients with ER+ HER2- MBC and showed no significant difference compared to letrozole alone. This data adds favorably to the significant improvement in PFS seen in PALOMA-2.

Clinical trial identification

Pfizer: NCT01740427

Legal entity responsible for the study

Pfizer, Inc


Pfizer, Inc


H. Rugo: Institution receives research funding from Pfizer, Novartis, Lilly. V. Dieras: Consultant/Advisory role -Roche, Pfizer, Novartis Speaker's Bureau-Roche, Pfizer, Novartis. R. Finn: Consultant/Advisory role -Pfizer, Bayer, Novartis, Bristol Myers Squibb Institution receives research funding from Pfizer.

D. Slamon: Stock Ownership; Travel Accommodations or Expenses -PFizer Leadership; Stock Ownership; Travel Accommodations or Expenses- BioMarin. M. Miguel: Honraria - Amgen, Novartis Consultant/Advisory Role -Celgene; Novartis; Pfizer; Roche Pharma AG Research funding – Novartis.

J. Ettl: Consulting or Advisory Role; Travel Accommodations or Expenses - Pfizer, Roche, GSK, Teva, Novartis. A. Mori, D.R. Lu, H. Bhattacharyya, C.H. Bartlett, S. Iyer: Pfizer employee and stockholder

S. Johnston: Research Funding - Pfizer Consultant/Advisory Board - Astra Zeneca, Roche/Genetech, Novartis, Puma. N. Harbeck: Honararia-Amgen; Celgene, NanoString Technologies, Novartis; Pfizer, Roche.Consultant/Advisory Role -AstraZeneca, Celgene, Genomic Health, Novartis, Roche/Genentech, Sandoz, Wilex.Research Funding -Boehringer Ingelheim, Novartis, Pfizer, Roche/Genentech. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings